Serum hyaluronic acid and laminin in children with chronic hepatitis B

Vajro, Pietro; Chiara, Carolina De; D’Armiento, Maria; Vincenzo, Anna De; Guarnaccia, D.; Terracciano, Luigi; Vecchione, R; Fontanella, Angiola

doi:10.1097/00042737-199411000-00009

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The high incidence of splenomegaly in this population is perhaps not surprising when it is considered that splenomegaly is 1 of the indications for biopsy. However, the presence of splenomegaly in even mild disease is interesting and perhaps additional evaluation of sinusoidal capillarisation in these children may be valuable as reported by Vajro et al (26).…”

Section: Discussionmentioning

confidence: 85%

Serum Levels of CK18 M30 and Leptin Are Useful Predictors of Steatohepatitis and Fibrosis in Paediatric NAFLD

Fitzpatrick

Mitry

Quaglia

et al. 2010

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 85%

Serum Levels of CK18 M30 and Leptin Are Useful Predictors of Steatohepatitis and Fibrosis in Paediatric NAFLD

Fitzpatrick

Mitry

Quaglia

et al. 2010

J. pediatr. gastroenterol. nutr.

View full text Add to dashboard Cite

show abstract

“…In children, serum HA and/or laminin has already been shown to be promising for the prediction of hepatic fibrosis in children with other chronic hepatopathies (117). It has been shown that the serum levels of HA alone are predictors of the degree of hepatic fibrosis in children with NAFLD (118).…”

Section: Fibrosis Markersmentioning

confidence: 99%

Diagnosis of Nonalcoholic Fatty Liver Disease in Children and Adolescents

Vajro

Lenta

Socha

et al. 2012

J. pediatr. gastroenterol. nutr.

Self Cite

467

485

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in children and adolescents in the United States, and most probably also in the rest of the industrialized world.As the prevalence of NAFLD in childhood increases with the worldwide obesity epidemic, there is an urgent need for diagnostic standards that can be commonly used by pediatricians and hepatologists. To this end, we performed a PubMed search of the adult and pediatric literature on NAFLD diagnosis through May 2011 using Topics and/or relevant Authors as search words. According to the present literature, NAFLD is suspected based on the association of fatty liver combined with risk factors (mainly obesity), after the exclusion of other causes of liver disease. The reference but imperfect standard for confirming NAFLD is liver histology. The following surrogate markers are presently used to estimate degree of steatosis and liver fibrosis and risk of progression to end-stage liver disease: imaging by ultrasonography or magnetic resonance imaging, liver function tests, and serum markers of liver fibrosis.NAFLD should be suspected in all of the overweight or obese children and adolescents older than 3 years with increased waist circumference especially if there is a NAFLD history in relatives. The typical presentation, however, is in children ages 10 years and older. The first diagnostic step in these children should be abdominal ultrasound and liver function tests, followed by exclusion of other liver diseases. Overweight/obese children with normal ultrasonographic imaging and normal liver function tests should still be monitored due to the poor sensitivity of these tests at a single assessment.Indications for liver biopsy include the following: to rule out other treatable diseases, in cases of clinically suspected advanced liver disease, before pharmacological/surgical treatment, and as part of a structured intervention protocol or clinical research trial.

show abstract

An update on the strategies used for the treatment of chronic hepatitis B in children

Clemente

Vajro²

2016

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Chronic hepatitis B (CHB) in children shows a variety of clinical presentations, which influence its natural course and treatment options. This report provides an overview of the ongoing strategies in pediatric CHB management. Interferon-α represents the first choice of treatment in children showing HBV replication and hepatic inflammation (immune active CHB), while the recommendation is to monitor inactive/immune-tolerant children (normal transaminases and low/absent viral replication). When circumstances preclude the use of Interferon-α and in cases of compensated/decompensated cirrhosis, entecavir for children above 2 years of age or tenofovir for children above 12 years of age are the nucleos(t)ide analogues recommended by the most recent guidelines.

show abstract

Serum hyaluronic acid and laminin in children with chronic hepatitis B

Cited by 3 publications

References 0 publications

Serum Levels of CK18 M30 and Leptin Are Useful Predictors of Steatohepatitis and Fibrosis in Paediatric NAFLD

Serum Levels of CK18 M30 and Leptin Are Useful Predictors of Steatohepatitis and Fibrosis in Paediatric NAFLD

Diagnosis of Nonalcoholic Fatty Liver Disease in Children and Adolescents

An update on the strategies used for the treatment of chronic hepatitis B in children

Contact Info

Product

Resources

About